PharVision Advisers’s Cognex CGNX Stock Holding History

PharVision Advisers’s Portfolio CGNX Stock Details CGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,696	Closed	-$385K	–	202
2025 Q4	$385K	Buy	+10,696	New	+$433K	0.19%	145

Other funds holding CGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PharVision Advisers's CGNX Position: Q1 2026 in Review

PharVision Advisers sold out of Cognex (CGNX) in Q1 2026, closing a stake of 10,696 shares — an estimated $385K sold.

PharVision Advisers first reported a position in CGNX in Q4 2025 and held it in 1 quarter. The position peaked at $385K in Q4 2025. 575 funds tracked by Wall St. Rank hold CGNX as of Q1 2026.

PharVision Advisers reported no remaining Cognex position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 10,696 Cognex shares in Q1 2026, an estimated $385K.
PharVision Advisers first reported a position in Cognex in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Cognex position peaked at $385K in Q4 2025.
575 funds tracked by Wall St. Rank held Cognex as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.